SailPoint Provides Customers the Freedom of Choice in Identity Governance Deployment: SaaS, Public Cloud, Data Center, or Managed Service
SailPoint Technologies Holdings, Inc. (NYSE: SAIL), the leader in enterprise identity governance , today unveiled the company’s comprehensive delivery strategy that provides customers with deployment options for their identity governance platform, spanning: software-as-a-service, in the public cloud, in their own data center or from a managed service provider. SailPoint is the first and only vendor to offer a comprehensive identity governance platform while providing customers with the freedom to choose the deployment option that best suits their needs.
“Global enterprises face a myriad of changing business requirements, which in turn is forcing them to evolve their infrastructure. Some organizations are moving to a cloud-first strategy while others are looking for a delivery option that reduces their needs for skilled staff and limits infrastructure capital expenses,” said Kevin Cunningham, Chief Strategy Officer and Co-founder for SailPoint. “Regardless of their preference in approach, every enterprise needs an identity governance platform that manages their entire hybrid IT environment. We found that providing our customers with a comprehensive set of deployment options gave them the freedom to choose the identity governance delivery strategy that best aligns with their infrastructure strategy.”
SailPoint’s Customer-Driven Delivery Strategy
Global enterprises can choose to deploy SailPoint’s market-leading identity governance solutions via the following comprehensive options:
- SaaS: Delivered as a turn-key SaaS offering to enable mid-sized enterprises to rapidly adopt a comprehensive approach to identity that takes advantage of the fast time-to-value and ease-of-use that SaaS provides
- Public Cloud: Customer hosted in a public cloud platform (like Amazon Web Services or Microsoft Azure) to maximize the benefits of a fully owned and operated identity governance platform balanced with the agility and efficiencies of the public cloud
- Data Center: Deployed on premises, for those organizations with a desire to maintain complete control of their identity infrastructure while addressing the sophisticated needs of the large enterprise environment
- Managed Service: Hosted and delivered by a trusted Managed Service Provider, delegating some or all identity governance administration to a proven service provider to assess, deploy, manage and support overall identity efforts
“The market has matured and evolved with enterprises now having varying preferences in deployment models,” continued Cunningham. “While some of our largest customers favor migration to the public cloud, others choose to remain on-premises. On the other hand, a fast-emerging mid-market enterprise company may favor a SaaS offering. Between the two is the emerging MSP market. We are pleased to be offering our customers a choice in deployment options.”
SailPoint works with a range of MSP partners including the global systems integrators and regional resellers. Some of our current partners include Accenture, Column Technologies, Grabowsky, IDMWORKS, NNIT and PwC.
“Our clients want immediate value from identity governance tools. They need fast deployment patterns, platform variety and security services to ensure resiliency is delivered for internal and external users as capabilities scale,” said Rex Thexton, managing director, Digital Identity, Accenture Security. “This combined with an identity governance strategy delivers the critical security-first approach that is needed to help our clients drive risk out of their programs with velocity.”
“Our customers are looking for the quickest time to value when deploying an identity governance program,” said Richard Mardling, Director, Identity & Access Management, PwC. “By offering a variety of deployment options, including the ability to deploy as a managed service, we can tailor identity governance programs for our customers that best suits their business environment. This enables our customers to more quickly realize the impact that identity has on their business.”
To learn more about how SailPoint’s comprehensive deployment options can help enterprises of all sizes deploy an identity governance program, please attend our webinar, “The Power of Choice – Identity Governance for your Modern Enterprise” on Wednesday, April 11, 2018 at 10 am CST | 4 pm GMT.
SailPoint: The Power of Identity™
SailPoint, the leader in enterprise identity governance, brings the Power of Identity to customers around the world. SailPoint’s open identity platform gives organizations the power to enter new markets, scale their workforces, embrace new technologies, innovate faster and compete on a global basis. As both an industry pioneer and market leader in identity governance, SailPoint delivers security, operational efficiency and compliance to enterprises with complex IT environments. SailPoint's customers are among the world’s largest companies in a wide range of industries, including: 6 of the top 15 banks, 4 of the top 6 healthcare insurance and managed care providers, 8 of the top 15 property and casualty insurance providers, 5 of the top 15 pharmaceutical companies, and 11 of the largest 15 federal agencies.
SailPoint, the SailPoint logo, IdentityIQ, IdentityNow, IdentityAI, SecurityIQ and all techniques are trademarks or registered trademarks of SailPoint Technologies Holdings, Inc. in the U.S. and/or other countries. All other products or services are trademarks of their respective companies.
SailPoint Technologies Holdings, Inc.
Jessica Sutera, 978-278-5411
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Celltrion Completes Resubmission to FDA for Proposed Trastuzumab Biosimilar18.6.2018 05:53 | Tiedote
Celltrion (KRX:068270) has made a resubmission to the FDA (U.S. Food and Drug Administration) to obtain its marketing approval for CT-P6, a proposed mAb biosimilar to Herceptin® (trastuzumab). Celltrion submitted its abbreviated Biologics License Applications (aBLAs) for CT-P10 and CT-P6 to the FDA in April and May of last year, respectively. However, it received CRLs (complete response letters) from the FDA related to the warning letter issued by the FDA in January 2018, related to the manufacturing facility in Incheon, South Korea. Celltrion had completed the resubmission for the approval of CT-P10, a proposed biosimilar to Rituxan® (rituximab) last month. In accordance with FDA regulations, the approval procedure will be usually finalized within six months from the resubmission, so Celltrion expects the approval for the U.S. market of the two proposed biosimilars within this calendar year. FDA has notified Celltrion of its re-inspection schedule regarding regular audit results, and
CES Asia: Innovation at the Speed of 5G15.6.2018 17:59 | Tiedote
CES Asia® 2018 wrapped today with the rapid pace of global innovation front and center over the show’s three day duration. The next stage of technology advancements were showcased across vehicle tech, robotics, artificial intelligence (AI), virtual and augmented reality, digital health and more. The event, 24 percent larger than last year in terms of footprint, cemented itself as the place to fully experience how the pace of technology is accelerating globally. CES Asia, the premier event for tech innovation in the Asian marketplace, will return to Shanghai, China, June 11-13, 2019. “5G and AI are igniting growth across the entire tech ecosystem changing the way we interact with technology and the world around us,” said Gary Shapiro, president and CEO, Consumer Technology Association (CTA)™. “It’s incredible to see technology refining and reinventing itself at such a fast pace. Just six months ago we were at CES with life-altering tech all around us. This week, I saw that technology re
bluebird bio Announces New Interim Data from Phase 1 (HGB-206) Study of LentiGlobin™ Gene Therapy in Patients with Severe Sickle Cell Disease at Annual Congress of the European Hematology Association15.6.2018 13:00 | Tiedote
bluebird bio, Inc. (Nasdaq: BLUE) today announced new interim data from the ongoing HGB-206 Phase 1 multicenter clinical study of LentiGlobin investigational gene therapy in patients with severe sickle cell disease (SCD) will be presented in an oral presentation on Saturday, June 16 at the 23rd Congress of the European Hematology Association (EHA) by Julie Kanter, M.D., Medical University of South Carolina, Charleston, South Carolina. “The consistent production of increased amounts of anti-sickling HbAT87Q in the Group C patients reflects the substantial positive impact of the changes introduced with the amended HGB-206 study protocol and refined manufacturing process. All four Group C patients with greater than or equal to three months follow-up are making over 30 percent anti-sickling HbAT87Q. The first patient treated, now with six months of follow-up, is producing over 60 percent anti-sickling HbAT87Q with a normal total hemoglobin level of 14.2 g/dL,” said David Davidson, M.D., ch
bluebird bio Presents New Data from Northstar (HGB-204) and Northstar-2 (HGB-207) Studies of LentiGlobin™ Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia at Annual Congress of the European Hematology Association15.6.2018 13:00 | Tiedote
bluebird bio, Inc. (Nasdaq: BLUE) announced that new data from the completed Phase 1/2 Northstar (HGB-204) study in adolescents and adults with transfusion-dependent β-thalassemia (TDT) and any genotype, and its ongoing, Phase 3 Northstar-2 (HGB-207) multicenter clinical study of LentiGlobin™ investigational gene therapy in patients with TDT and non-β0/β0 genotypes, will be presented in an oral session on June 16 at the 23rd Annual Congress of the European Hematology Association by Franco Locatelli, M.D., Ph.D., of the IRCCS Ospedale Pediatrico Bambino Gesù of Rome, Italy. “The maturing data from HGB-204 and HGB-207 suggest that one-time treatment with LentiGlobin may address the underlying genetic cause of TDT. With our refined manufacturing process, the majority of patients with TDT and non-β0/β0 genotypes are transfusion-free and producing total hemoglobin at normal or near-normal levels,” said David Davidson, M.D., chief medical officer, bluebird bio. “We are on track to submit a m
AGP Group Announces the Acquisition of Soliver NV in Belgium, Representing a Key Step towards Becoming the Premier Global Leader in Designing and Manufacturing High-Tech Automotive Glazing15.6.2018 12:00 | Tiedote
AGP, a high-tech specialty glass designer and manufacturer, has announced today the acquisition of Soliver NV, a European automotive glazing manufacturer with over 65 years of solid product and brand reputation. Soliver offers high-quality tempered and laminated glazing for high-end automobiles, as well as windshield solutions for trucks. AGP’s glazing heritage started in Berlin, with the Mannheim family´s first glass company. After 100 years and a clear vision to become a leader in specialty glass, AGP’s core eGlass technologies have responded to the rising demand in electrification, connectivity, shared mobility and autonomous driving, acting as an enabler of future mobility trends. The integration of Soliver into the AGP Group will strengthen the AGP eGlass value proposition and will be a game changer in a fast-evolving industry. “We are very excited to build upon Soliver’s great experience and track-record to take high-tech glazing to the next level, enabling our customer’s product
Rivoli Group announces completion of its new international corporate strategy15.6.2018 10:00 | Tiedote
Rivoli Group AG completes its comprehensive operational restructuring process and acts with a new presence in the future. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180615005085/en/ Rivoli Group Announces Completion of Its New International Corporate Strategy (Photo: Business Wire) The Swiss based Rivoli Group AG has now completed the comprehensive restructuring process as part of the international realignment of its corporate strategy. After an intensive evaluation of the situation, the available resources and existing market potential, the Chairman of the Board of Directors Mr. Mourad Malloul, the management team and an international advisory committee coordinated the strategy together. "This is the beginning of a crucial new chapter for the Rivoli Group," the President and CEO of Rivoli Group AG said. The measure aims to strengthen the competitive advantages within the company group, to adjust their service offerings
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme